6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A clinical review of sermorelin acetate FAERS safety signals, FDA adverse-event reporting patterns, post-market surveillance findings, and what the data means for prescribers and patients.
A complete regulatory history of sermorelin acetate, from its 1997 FDA approval through voluntary market withdrawal and current 503A compounding status, with clinical trial data and safety context.
A complete guide to sermorelin's FDA approval history, current compounding pharmacy status, global regulatory standing, label requirements, and post-market safety data. Reviewed by HealthRX.com physicians.
A comprehensive review of sermorelin acetate label changes, FDA regulatory actions, compounding pharmacy status, and post-market safety data from 2020 through 2026.
A clinical review of sermorelin acetate's regulatory history, current compounding status, and the next-generation GHRH analogs and GH secretagogues in development that may reshape growth hormone therapy.
A detailed comparison of how the FDA and EMA have handled sermorelin acetate, from its original 1997 approval through withdrawal and current compounding status.